Black Diamond Therapeutics
BDTX
95 hedge funds and large institutions have $124M invested in Black Diamond Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 27 closing their positions.
3.27% less ownership
Funds ownership: 67.32% → 64.05% (-3.3%)
6% less funds holding
Funds holding: 101 → 95 (-6)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
40% less capital invested
Capital invested by funds: $206M → $124M (-$82.3M)
67% less call options, than puts
Call options by funds: $87K | Put options by funds: $260K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.69M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.44M |
| 3 |
BlackRock
New York
|
+$404K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$323K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.43M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$4.44M |
| 3 |
SG Americas Securities
New York
|
-$2.29M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$649K |
| 5 |
HF
HRT Financial
New York
|
-$604K |
BDTX Hedge Fund Activity: Q4 2021 in Review
95 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2021, worth a combined $124M — down 40% from $206M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of BDTX and 21 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 21 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.69M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.43M sold.
- 95 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2021, down from 101 in Q3 2021.
- Funds reported $124M of Black Diamond Therapeutics stock for Q4 2021, down 40% quarter-over-quarter.
- 21 funds opened new Black Diamond Therapeutics positions in Q4 2021 and 27 closed out, a net change of -6 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $2.69M added.
- The largest Black Diamond Therapeutics seller in Q4 2021 was Deerfield Management, an estimated $6.43M sold.
Based on aggregated 13F filings for Q4 2021.